Clinical studies have established that ABCB1 expression levels are high in advanced stages of CML, and that high ABCB1 expression is associated with lower MMR rate and resistance to TKIs (23, 24). Here, ABCB1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.